BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Policy

  FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

  Fennec Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has issued a public reminder to healthcare providers that PEDMARK is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label.

  February 1, 2024

   · 

  2 min read
• Biotech Beach

  Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

  Revelation Biosciences Inc. announced the pricing of a public offering of 1,365,000 shares of its common stock, together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of $4.53 per share and associated warrant.

  February 1, 2024

   · 

  5 min read
• Business

  BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS

  Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023.

  February 1, 2024

   · 

  22 min read
• Business

  BD Reports First Quarter Fiscal 2024 Financial Results

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2024, which ended December 31, 2023.

  February 1, 2024

   · 

  28 min read
• Business

  Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2023.

  February 1, 2024

   · 

  39 min read
• Pharm Country

  Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

  Krystal Biotech, Inc. today announced that the Company will participate in the Guggenheim 6th Annual Biotechnology Conference, which takes place in New York on February 7-8.

  February 1, 2024

   · 

  1 min read
• Business

  Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

  Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended December 31, 2023, on Wednesday, February 7, 2024.

  February 1, 2024

   · 

  3 min read
• Drug Development

  Purple Biotech Reaches Recommended Phase 2 Dose for NT219

  Purple Biotech Ltd. today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study (NCT04474470).

  February 1, 2024

   · 

  8 min read
• Revive Therapeutics Explores the Use of Bucillamine for Long COVID

  Revive Therapeutics Ltd. announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

  February 1, 2024

   · 

  4 min read
• Business

  Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors

  Graviton Bioscience along with other therapeutic compounds, announces a strategic investment from Sanofi.

  February 1, 2024

   · 

  3 min read